IP Verse

Cells For Immunotherapy Engineered For Targeting Antigen Present Both On Immune Cells And Pathological Cells - EP3105317

EP3105317

CELLECTIS
Application Number
EP15706399A
Filing Date
Feb 13, 2015
Status
Opposition Rejected
Feb 4, 2022
Grant Date
Sep 19, 2018
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP4368705B1
EP2997141B1
EP3116902B1

Bibliography

The patent EP3105317B1 was granted to Cellectis on Sep 19, 2018 following the initial filing on Feb 13, 2015 under the application number EP15706399A . The current legal status of the patent is Opposition Rejected.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

JAMES POOLEJun 19, 2019ADMISSIBLE
SCHIWECK WEINZIERL KOCH PATENTANWALTE PARTNERSCHAFT MBBJun 19, 2019ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents